Investor Center Home
Corporate Profile
Bellicum is a clinical-stage biopharmaceutical company that’s driving the future of cellular immuno-oncology (IO). We discover and develop product candidates in some of the most important areas of cellular immunotherapy, with a current focus on CAR-T therapies for solid tumors.
Bellicum has engineered the newest wave of high-performance cellular technology, unleashing the power of potentially curative IO therapies against a wide range of cancers, providing a better tomorrow for more cancer patients.
(Common Stock)
-
(US Dollar)
-
Price
-
Change
-
(%)Volume
-
Exchange
NASDAQ
Data as of 02/01/23 5:11 PM EST
Copyright West LLC. Minimum 15 minutes delayed.
